BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26903311)

  • 21. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
    Berenson JR; Hilger JD; Yellin O; Boccia RV; Matous J; Dressler K; Ghazal HH; Jamshed S; Kingsley EC; Harb WA; Noga SJ; Nassir Y; Swift RA; Vescio R
    Ann Hematol; 2014 Jan; 93(1):89-98. PubMed ID: 24135804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
    Offidani M; Polloni C; Cavallo F; Liberati AM; Ballanti S; Pulini S; Catarini M; Alesiani F; Corvatta L; Gentili S; Caraffa P; Boccadoro M; Leoni P; Palumbo A
    Leuk Lymphoma; 2012 Sep; 53(9):1722-7. PubMed ID: 22335534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma.
    Wahaib K; Beggs AE; Campbell H; Kodali L; Ford PD
    Am J Health Syst Pharm; 2016 Apr; 73(7):441-50. PubMed ID: 27001985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.
    Wieduwilt MJ; Pawlowska N; Thomas S; Olin R; Logan AC; Damon LE; Martin T; Kang M; Sayre PH; Boyer W; Gaensler KML; Anderson K; Munster PN; Andreadis C
    Clin Cancer Res; 2019 Aug; 25(16):4917-4923. PubMed ID: 31152020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
    Kobayashi Y; Munakata W; Ogura M; Uchida T; Taniwaki M; Kobayashi T; Shimada F; Yonemura M; Matsuoka F; Tajima T; Yakushijin K; Minami H
    Int J Hematol; 2018 Jan; 107(1):83-91. PubMed ID: 28905323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
    Mascarenhas J; Lu M; Li T; Petersen B; Hochman T; Najfeld V; Goldberg JD; Hoffman R
    Br J Haematol; 2013 Apr; 161(1):68-75. PubMed ID: 23330839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.
    Fukutomi A; Hatake K; Matsui K; Sakajiri S; Hirashima T; Tanii H; Kobayashi K; Yamamoto N
    Invest New Drugs; 2012 Jun; 30(3):1096-106. PubMed ID: 21484248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
    Tan WW; Allred JB; Moreno-Aspitia A; Northfelt DW; Ingle JN; Goetz MP; Perez EA
    Clin Breast Cancer; 2016 Apr; 16(2):82-6. PubMed ID: 26774555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors.
    Jones SF; Infante JR; Thompson DS; Mohyuddin A; Bendell JC; Yardley DA; Burris HA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):471-5. PubMed ID: 22851205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
    Wood A; George S; Adra N; Chintala S; Damayanti N; Pili R
    Invest New Drugs; 2020 Aug; 38(4):1108-1116. PubMed ID: 31654285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
    Becerra CR; Verma UN; Tran HT; Tavana D; Williams NS; Frenkel EP
    Am J Clin Oncol; 2008 Jun; 31(3):219-25. PubMed ID: 18525298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients.
    Høgh Kølbæk Kjær AS; Brinkmann CR; Dinarello CA; Olesen R; Østergaard L; Søgaard OS; Tolstrup M; Rasmussen TA
    AIDS; 2015 Jun; 29(10):1195-200. PubMed ID: 25870990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.
    Ocio EM; Herrera P; Olave MT; Castro N; Pérez-Simón JA; Brunet S; Oriol A; Mateo M; Sanz MÁ; López J; Montesinos P; Chillón MC; Prieto-Conde MI; Díez-Campelo M; González M; Vidriales MB; Mateos MV; San Miguel JF;
    Haematologica; 2015 Oct; 100(10):1294-300. PubMed ID: 26160880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.
    Shapiro GI; Frank R; Dandamudi UB; Hengelage T; Zhao L; Gazi L; Porro MG; Woo MM; Lewis LD
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):555-62. PubMed ID: 22057852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.
    Wood PJ; Strong R; McArthur GA; Michael M; Algar E; Muscat A; Rigby L; Ferguson M; Ashley DM
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):493-503. PubMed ID: 29987369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
    DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
    Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
    Tan D; Phipps C; Hwang WY; Tan SY; Yeap CH; Chan YH; Tay K; Lim ST; Lee YS; Kumar SG; Ng SC; Fadilah S; Kim WS; Goh YT;
    Lancet Haematol; 2015 Aug; 2(8):e326-33. PubMed ID: 26688485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.
    Talbot SM; Westerman DA; Grigg AP; Toner GC; Wolf M; Bishop J; McKendrick J; Zalcberg J; Levi J; Fox RM; Green MD
    Ann Oncol; 1999 Aug; 10(8):907-14. PubMed ID: 10509151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
    Mu S; Kuroda Y; Shibayama H; Hino M; Tajima T; Corrado C; Lin R; Waldron E; Binlich F; Suzuki K
    Eur J Clin Pharmacol; 2016 Feb; 72(2):153-61. PubMed ID: 26494130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
    Munster P; Marchion D; Bicaku E; Lacevic M; Kim J; Centeno B; Daud A; Neuger A; Minton S; Sullivan D
    Clin Cancer Res; 2009 Apr; 15(7):2488-96. PubMed ID: 19318486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.